2. Inflammation/Immunology

Inflammation/Immunology (炎症/免疫)

Inflammation/Immunology

関連製品

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

製品番号 製品名 CAS 番号 純度 構造式
  • HY-160615
    TP receptor antagonist-1 1448452-21-8 98%
    TP receptor antagonist-1 (compound 7m) is a thromboxane A2 receptor (TP receptor) antagonist, with IC50 values of 9.46 μM for TPa and 8.49 μM for TPb, respectively. TP receptor antagonist-1 can be used for the research of cardiovascular disease.
    TP receptor antagonist-1
  • HY-160647
    CCR8 antagonist 3 912463-57-1 98%
    CCR8 antagonist 3 (compound 2) is a CCR8 antagonist with an IC50 value of 0.062 µM. CCR8 antagonist 3 shows human microsomal stability.
    CCR8 antagonist 3
  • HY-160658
    AZ760 912461-36-0 98%
    AZ760 is a CCR8 antagonist. AZ760 shows excellent potency, good lipophilicity and high free fraction in blood. AZ760 exhibits unacceptable hERG inhibition.
    AZ760
  • HY-160713
    Betamethasone succinate 27297-42-3
    Betamethasone succinate (NSSL-BMS) is a nano-formulation that can cross the blood-brain barrier. Betamethasone succinate is prepared by encapsulating the Betamethasone (HY-13570) semi-succinate in PEG-liposomes. Betamethasone succinate utilizes the enhanced permeation and retention effects of liposomes to target and deliver the potent glucocorticoid to the inflammatory sites. Betamethasone succinate inhibits the secretion of pro-inflammatory cytokines (such as TNF-α and IL-6) while maintaining the level of anti-inflammatory cytokine TGF-β. Betamethasone succinate can be used in the research of arthritis and cerebral malaria.
    Betamethasone succinate
  • HY-160930
    TOP1288 1630202-02-6 98%
    TOP1288 is a narrow spectrum kinase inhibitor for P38α, Src and Syk kinase, with IC50 of 116nM, 24nM and 659nM, respectively. TOP1288 inhibits inflammatory cytokine release from inflamed biopsies and myofibroblasts.
    TOP1288
  • HY-161043
    ECDD-S16 98%
    ECDD-S16 is a potent inhibitor of pyroptosis. ECDD-S16 inhibits surface and endosomal TLR ligands activated pyroptosis in Raw264.7 cells.
    ECDD-S16
  • HY-16125R
    Carboxyamidotriazole Orotate (Standard) 187739-60-2 98%
    Carboxyamidotriazole (Orotate) (Standard) is the analytical standard of Carboxyamidotriazole (Orotate). This product is intended for research and analytical applications. Carboxyamidotriazole Orotate (L-651582 Orotate) is the orotate salt form of Carboxyamidotriazole (CAI), an orally bioavailable signal transduction inhibitor. Carboxyamidotriazole Orotate is a cytostatic inhibitor of nonvoltage-operated calcium channels and calcium channel-mediated signaling pathways. Carboxyamidotriazole Orotate shows anti-tumor, anti-inflammatory and antiangiogenic effects.
    Carboxyamidotriazole Orotate (Standard)
  • HY-16126R
    Carboxyamidotriazole (Standard) 99519-84-3 98%
    Carboxyamidotriazole (Standard) is the analytical standard of Carboxyamidotriazole. This product is intended for research and analytical applications. Carboxyamidotriazole (L-651582) is a cytostatic inhibitor of nonvoltage-operated calcium channels and calcium channel-mediated signaling pathways. Carboxyamidotriazole shows anti-tumor, anti-inflammatory and antiangiogenic effects.
    Carboxyamidotriazole (Standard)
  • HY-161551
    25-OH Vitamin D3/KLH 98%
    25-OH Vitamin D3/KLH is an antigen-adjuvant conjugate of 25-OH Vitamin D3 (HY-158285) and Keyhole Limpet Hemocyanin (KLH). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
    25-OH Vitamin D3/KLH
  • HY-161565
    Gastrin(1-17)/BSA 98%
    Gastrin(1-17)/BSA is an antigen-adjuvant conjugate formed by the coupling of Gastrin(1-17) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or destroy major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
    Gastrin(1-17)/BSA
  • HY-161612
    Mycosporine 2 glycine 149092-45-5 98%
    Mycosporine 2 glycine is an anti-inflammatory agent and TYRP1 inhibitor. Mycosporine 2 glycine inhibits the expression of inflammatory genes and reduces nitric oxide production. Mycosporine 2 glycine binds tightly to the active pocket of TYRP1 and inhibits the activity of melanogenesis-related enzymes. Mycosporine 2 glycine can be used in the research of hyperpigmentation and inflammation-related diseases.
    Mycosporine 2 glycine
  • HY-161907
    h15-LOX-2 inhibitor 2 98%
    h15-LOX-2 inhibitor 2 (Compound 10) is an inhibitor of h15-LOX, with IC50 and Ki values of 26.9 μM and 16.4 μM, respectively.
    h15-LOX-2 inhibitor 2
  • HY-161908
    h15-LOX-2 inhibitor 3 1164515-84-7 98%
    h15-LOX-2 inhibitor 3 (Compound 13) is an inhibitor of h15-LOX, with IC50 and Ki values of 25 μM and 15.1 μM, respectively.
    h15-LOX-2 inhibitor 3
  • HY-161935
    6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid 98%
    6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid (Compound 2) exhibits antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin enterococci (VRE). 6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid interfers with the integrity and function of the bacterial cell membrane, and affects metabolism in MRSA. 6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid exhibits anti-inflammatory and anti-infective efficacy, and promotes angiogenesis in mice.
    6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid
  • HY-161988
    Antimicrobial agent-34 3055131-42-2 98%
    Antimicrobial agent-34 (compound 4h) is an antibacterial agent (MIC = 1–4 μg/mL), with a clogP value of 9.14. Antimicrobial agent-34 has good plasma stability (HC50 of 131.1 μg/mL) and good membrane selectivity (HC50/MIC is 65.6), with rapid sterilization capability. Antimicrobial agent-34 destroys the integrity of bacterial cell membranes, induces an increase in intracellular reactive oxygen species, and leaks protein and DNA, ultimately leading to bacterial death. Antimicrobial agent-34 demonstrates significant in vivo antibacterial potency in a mouse sepsis model infected with Staphylococcus aureus ATCC43300.
    Antimicrobial agent-34
  • HY-162015
    LTA4H-IN-2 2851480-52-7 98%
    LTA4H-IN-2 (compound (S)-2 ) is an orally active inhibitor of Leukotriene A4 Hydrolase, with an IC50 of <3 nM.
    LTA4H-IN-2
  • HY-162044
    COX-1/2-IN-6 327024-84-0 98%
    COX-1/2-IN-6 (compound 4 h) is a potent dual inhibitor of COX-1 and COX-2 with IC50s of 68 and 91 nM, respectively. COX-1/2-IN-6 can used in study inflammation diseases.
    COX-1/2-IN-6
  • HY-162579
    TLR7 agonist 22 3036114-68-5 98%
    TLR7 agonist 22 (Compound 11a) emerges as a selective TLR7 agonist with an IC50 value of 25.86 μM. TLR7 agonist 22 inhibits the cellular HBsAg secretion and effectively activates TLR7, thereby inducing the secretion of TLR7-regulated cytokines IL-12, TNF-αand IFN-αin human PBMC cells. TLR7 agonist 22 is a promising for research in the field of developing novel immunomodulatory anti-HBV agents.
    TLR7 agonist 22
  • HY-162615
    Antibacterial agent 225 3047459-82-2 98%
    Antibacterial agent 225 (compound 12a-2) simultaneously exerts excellent bifunctional effects of fungal inhibition and immune activation.
    Antibacterial agent 225
  • HY-162700
    MK2-IN-6 98%
    MK2-IN-6 (Compound 11) is a potent and selective irreversible MK2 inhibitor with an IC50 value of 2.3 nM. MK2-IN-6 inhibits MK2 kinase activity, achieving prolonged MK2 signaling suppression and reducing pathological inflammatory cytokines in macrophages. MK2-IN-6 inhibits the M2-like protumor phenotype of macrophages both in vitro and in vivo, which is proming for research of colorectal cancer.
    MK2-IN-6
製品番号 製品名 / Synonyms Application Reactivity